vs

Side-by-side financial comparison of NETSTREIT Corp. (NTST) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

NETSTREIT Corp. is the larger business by last-quarter revenue ($57.1M vs $35.5M, roughly 1.6× RECURSION PHARMACEUTICALS, INC.). NETSTREIT Corp. runs the higher net margin — 10.0% vs -304.2%, a 314.3% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 24.3%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 20.1%).

NETSTREIT Corp. is a US-headquartered real estate investment trust (REIT) that specializes in acquiring and operating a diversified portfolio of single-tenant net lease commercial properties. Its asset portfolio covers retail, industrial and office categories, primarily catering to investment-grade corporate tenants across the United States market.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

NTST vs RXRX — Head-to-Head

Bigger by revenue
NTST
NTST
1.6× larger
NTST
$57.1M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+657.5% gap
RXRX
681.7%
24.3%
NTST
Higher net margin
NTST
NTST
314.3% more per $
NTST
10.0%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
20.1%
NTST

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NTST
NTST
RXRX
RXRX
Revenue
$57.1M
$35.5M
Net Profit
$5.7M
$-108.1M
Gross Margin
59.8%
Operating Margin
34.1%
-304.8%
Net Margin
10.0%
-304.2%
Revenue YoY
24.3%
681.7%
Net Profit YoY
235.9%
39.6%
EPS (diluted)
$0.32
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NTST
NTST
RXRX
RXRX
Q1 26
$57.1M
Q4 25
$52.5M
$35.5M
Q3 25
$48.3M
$5.2M
Q2 25
$48.3M
$19.2M
Q1 25
$45.9M
$14.7M
Q4 24
$44.1M
$4.5M
Q3 24
$41.4M
$26.1M
Q2 24
$39.6M
$14.4M
Net Profit
NTST
NTST
RXRX
RXRX
Q1 26
$5.7M
Q4 25
$1.3M
$-108.1M
Q3 25
$618.0K
$-162.3M
Q2 25
$3.3M
$-171.9M
Q1 25
$1.7M
$-202.5M
Q4 24
$-5.4M
$-178.9M
Q3 24
$-5.3M
$-95.8M
Q2 24
$-2.3M
$-97.5M
Gross Margin
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Operating Margin
NTST
NTST
RXRX
RXRX
Q1 26
34.1%
Q4 25
2.6%
-304.8%
Q3 25
1.3%
-3327.6%
Q2 25
6.8%
-916.8%
Q1 25
3.7%
-1297.9%
Q4 24
-12.3%
-4042.4%
Q3 24
-12.8%
-377.1%
Q2 24
-5.8%
-697.4%
Net Margin
NTST
NTST
RXRX
RXRX
Q1 26
10.0%
Q4 25
2.5%
-304.2%
Q3 25
1.3%
-3135.3%
Q2 25
6.8%
-894.2%
Q1 25
3.7%
-1373.3%
Q4 24
-12.3%
-3935.5%
Q3 24
-12.8%
-367.5%
Q2 24
-5.8%
-676.6%
EPS (diluted)
NTST
NTST
RXRX
RXRX
Q1 26
$0.32
Q4 25
$0.01
$-0.17
Q3 25
$0.01
$-0.36
Q2 25
$0.04
$-0.41
Q1 25
$0.02
$-0.50
Q4 24
$-0.07
$-0.56
Q3 24
$-0.07
$-0.34
Q2 24
$-0.03
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NTST
NTST
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$1.5B
$1.1B
Total Assets
$2.8B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Total Debt
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
$1.1B
$9.6M
Q3 25
$1.1B
$11.9M
Q2 25
$926.6M
$14.2M
Q1 25
$913.3M
$16.4M
Q4 24
$868.3M
$19.0M
Q3 24
$778.7M
$20.5M
Q2 24
$726.2M
$22.9M
Stockholders' Equity
NTST
NTST
RXRX
RXRX
Q1 26
$1.5B
Q4 25
$1.4B
$1.1B
Q3 25
$1.3B
$1.0B
Q2 25
$1.3B
$919.1M
Q1 25
$1.3B
$933.9M
Q4 24
$1.3B
$1.0B
Q3 24
$1.3B
$524.6M
Q2 24
$1.3B
$584.4M
Total Assets
NTST
NTST
RXRX
RXRX
Q1 26
$2.8B
Q4 25
$2.6B
$1.5B
Q3 25
$2.5B
$1.4B
Q2 25
$2.3B
$1.3B
Q1 25
$2.3B
$1.3B
Q4 24
$2.3B
$1.4B
Q3 24
$2.2B
$726.5M
Q2 24
$2.1B
$775.9M
Debt / Equity
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
0.76×
0.01×
Q3 25
0.84×
0.01×
Q2 25
0.70×
0.02×
Q1 25
0.70×
0.02×
Q4 24
0.65×
0.02×
Q3 24
0.58×
0.04×
Q2 24
0.55×
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NTST
NTST
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
$109.5M
$-46.1M
Q3 25
$28.0M
$-117.4M
Q2 25
$30.6M
$-76.4M
Q1 25
$22.1M
$-132.0M
Q4 24
$90.2M
$-115.4M
Q3 24
$25.1M
$-59.2M
Q2 24
$25.4M
$-82.2M
Free Cash Flow
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
FCF Margin
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Capex Intensity
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Cash Conversion
NTST
NTST
RXRX
RXRX
Q1 26
Q4 25
82.46×
Q3 25
45.27×
Q2 25
9.36×
Q1 25
13.06×
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NTST
NTST

Rental revenue (including reimbursable)$54.0M95%
Other$3.0M5%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons